Skip to content
BALCAO · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Zeo ScientifiX, Inc. ZEOX

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$5.2M
▲ 12.5% YoY
$-5.5M
$-741,000

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company’s principal product is Zofin™, a product derived from amniotic fluid and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles. The Company was incorporated in the state of Nevada on August 9, 2011, under the name “Bespoke Tricycles Inc.,” changed its name to “Biotech Products Services and Research, Inc.” effective November 4, 2015, to “Organicell Regenerative Medicine, Inc.” effective June 20, 2018 and assumed its current name of “Zeo ScientifiX, Inc.” effective February 20, 2024. Our executive offices are located at 3321 College Avenue, Suite 246, Davie, Florida and our telephone number is (888) 963-7881. As of October 31, 2025, we had 20 full-time employees and no part-time employees.

Written from the business description in Zeo ScientifiX, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 29 January 2026. Every sentence was checked against that document before publication.

Growth

USD 5.2M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 5.2 · Net income -5.5
2.5M5.0M-5.0M-10.0M
201120142017202020232025
Compound annual growth
−7.1%
+11.2%
+42.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +11.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2023 · Net -153.3%
-50%-100%-150%
201120182025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -0.7
-2M-3M
201120182025

Total assetsUSD 1.5M
EquityUSD -1.4M
CashUSD 221,000.00
Gross debtUSD 243,000.00
Net debtUSD 22,000.00
Current ratio0.33×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ZEOX, 15-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌
Income tax $B◌◌◌◌0.00.00.00.00.00.0◌◌◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌
EPS, diluted $−0.86−0.74−0.99−1.56−0.01−0.020.00−0.01−0.08−0.01−0.010.00−0.00◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————
ROE %——————————————−88.3
Shares out B0.010.010.010.011.130.940.500.440.110.100.100.15◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 68 reconciliationsAUDITED

Reconciled in 15 of the 15 fiscal years we could check. Eight checks were skipped: the balance sheet is not tagged before 2011. Six checks were skipped: EPS is not tagged before 2013. Four checks were skipped: revenue is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onOTC market
Incorporated inNevada
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image